LSE · MHC.L
MyHealthChecked PLC
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
Loading market information…
LSE · POLX.L · GBp
Stock price, earnings
Quote as of Dec 22, 2025, 04:40 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Polarean Imaging plc’s quoted price sits in the lower half of its reported 52-week range, 95.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Polarean Imaging plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Polarean Imaging plc is a medical technology company specializing in drug-device combinations, catering to the medical imaging industry across the U.S., Canada, Germany, and the U.K. Its core business involves the creation and market introduction of gas polarizer apparatus and their supporting accessories. Polarean crafts innovative equipment designed to upgrade conventional magnetic resonance imaging (MRI) scanners for detailed functional pulmonary assessment. A significant area of expertise is the application of hyperpolarized xenon gas (129Xe) as a unique imaging tracer. This allows for precise, regional visualization of ventilation and gas exchange within the lungs' most intricate airways, the vital tissue interface separating the lungs from the bloodstream, and the pulmonary vascular network, thereby presenting a groundbreaking diagnostic methodology. Additionally, the firm undertakes the design and production of specialized MRI radiofrequency coils, essential components for conducting 129Xe imaging within an MRI framework. Established in 2016, Polarean Imaging plc has its operational base in Durham, North Carolina.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.00-£0.00 (-12.25%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.5% below the high.
£0.06+£0.00 (+5.36%)
Feedback plc’s quoted price sits in the lower half of its reported 52-week range, 60.67% below the high.
£0.00£0.00 (0.0%)
ValiRx plc’s quoted price sits in the lower half of its reported 52-week range, 64.58% below the high.
£0.00-£0.00 (-1.06%)
Physiomics Plc’s quoted price sits in the lower half of its reported 52-week range, 47.44% below the high.
£0.00£0.00 (0.0%)
Trellus Health plc’s quoted price sits in the lower half of its reported 52-week range, 94.86% below the high.
£0.01-£0.00 (-5.0%)
Roquefort Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 68.33% below the high.
